Besides, metformin has been suggested as a novel drug to the patients with rheumatoid arthritis because it activates AMPK signaling, leading to the inhibition of mTOR and the differentiation of T cells in vitro and in vivo, thus reducing the invasion of fibroblast-like synovial cells (clinicaltrials.gov). The gene discussed is MTOR; the disease is rheumatoid arthritis.